Privacy Analytics > Resources > Events > Safely Innovating with Sensitive Data
Safely Innovating with Sensitive Data
Date of Event: November 3, 2021
Location: LinkedIn Live
If you’re looking to safely use and share your organization’s sensitive data while earning trust from stakeholders, this LinkedIn Live Event is for you.
Join Sarah Lyons, Head of Privacy Analytics, in a fireside chat with Len Usvyat, Vice President, Applied Data Science, Biostatistics, and Epidemiology at Fresenius Medical Care. They’ll be discussing ways to cut through the complexities of the data privacy landscape to help you move forward with confidence when leveraging data derived from information about people.
When the EU’s General Data Protection Regulation (GDPR) came into effect, Fresenius Medical Care and its affiliates were stuck sitting on insight-rich data, wondering how they could make the best use of it to improve renal patient care – while protecting privacy.
As founding members of the international, non-profit MONitoring Dialysis Outcomes (MONDO) consortium, Renal Research Institute and its partners, such as Fresenius Medical Care, found a solution to keep the vital data-sharing operation going.
Join us to find out how they did it and what it could mean for your organization. You’ll hear directly from an executive who’s leveraging sensitive data safely and responsibly to deliver significant benefits to business and society.
“Without Privacy Analytics, we would not have been able to continue with the initiative”
— Len Usvyat, Vice President, Applied Data Science, Biostatistics, and Epidemiology at Fresenius Medical Care
Event registration is now closed.
Len Usvyat is the Vice President of Applied Data Science, Biostatistics, and Epidemiology for Fresenius Medical Care.
Len Usvyat
Vice President, Applied Data Science, Biostatistics, and Epidemiology, Fresenius Medical Care
Situation: California’s Consumer Privacy Act inspired Comcast to evolve the way in which they protect the privacy of customers who consent to share personal information with them.
Situation: Integrate.ai’s AI-powered tech helps clients improve their online experience by sharing signals about website visitor intent. They wanted to ensure privacy remained fully protected within the machine learning / AI context that produces these signals.
Situation: Novartis’ digital transformation in drug R&D drives their need to maximize value from vast stores of clinical study data for critical internal research enabled by their data42 platform.
Situation: CancerLinQ™, a subsidiary of American Society of Clinical Oncology, is a rapid learning healthcare system that helps oncologists aggregate and analyze data on cancer patients to improve care. To achieve this goal, they must de-identify patient data provided by subscribing practices across the U.S.
Situation: Needed to ensure the primary market research process was fully compliant with internal policies and regulations such as GDPR.
Situation: Needed to enable AI-driven product innovation with a defensible governance program for the safe and responsible use
of voice-to-text data under Shrems II.
This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.